Torriden CELLMAZING Brightening Capsule Patch
Everything behind the verdicts on this product: the rule that fired for each concern, the three answers and the documents they rest on, every study on the row with the date it was opened, and the versions of the tables that produced them. Nothing here is edited by hand; it is generated from the same records the verdicts are.
The scaleRecommendedGoodSupportingEarly evidenceNot for thisAvoidhow it works
Engine 5.2.0 · rules 0.5.1 · evidence table ev-2026.10-r231 · computed October 13, 2026 · how we decide · the evidence table · the anchors
for Dehydration
Nothing here targets dehydration directly; humectant hydration is the recognised companion to treating it, and this pad does that without known triggers.
Nothing here targets the concern directly, but the product’s job — barrier care, gentle cleansing, photoprotection — is the recognised companion to treating it. Rinse-off products carrying leave-on actives land here too.
- Rule
- R8 → Supporting role. An active with early or mechanistic evidence only or an active researched for the concern and found wanting or an active with no evidence row for the concern yet; the product’s category job is a recognised companion to treating the concern.
q1 = plausible | none | not-assessed · supportive = true
Why this rule exists: The category's job (barrier care, humectant hydration, gentle cleansing, photoprotection) is the documented supportive role for this concern. This is the honest verdict for a moisturizer on an acne page.
Rule R8 decided 3,793 verdicts across the catalog; “Supporting role” is the verdict on 7,796 of 45,446. The full register. - Carrying active
- Niacinamide
- 1 · Standing
- Not assessed
No evidence row exists for this active and concern; it is in the research queue. - 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
- 3 · Tolerability
- Gentle
- Evidence dots
- Not from a trial row
- What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 25, 2026 (unchanged across rebuilds since then)
← Back to the verdict All dehydration products → Disclose a concentration or correct a fact →
for Hyperpigmentation
Niacinamide is a trial-supported active for hyperpigmentation; this pad carries it, though the concentration is not declared.
A trial-supported active, or a reference standard by mechanism, at a working level; or a first-line active below its studied range.
- Rule
- R5 → Good choice. A supported active (trial-backed, or a reference standard by mechanism); declared at a working strength, or a labelled active or at a plausible but undeclared level.
q1 = supported · q2 = adequate | plausible
Why this rule exists: Trial-supported or guideline-supported active, adequately or plausibly dosed.
Rule R5 decided 9,843 verdicts across the catalog; “Good choice” is the verdict on 10,340 of 45,446. The full register. - Carrying active
- Niacinamide
- 1 · Standing
- Supported — trials support it
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
- 3 · Tolerability
- Gentle
- Evidence dots
- Moderate evidence
- What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 25, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer — British Journal of Dermatology (2002), opened July 16, 2026
- Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin — International Journal of Cosmetic Science (2004), opened July 16, 2026
- Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial — Skin Research and Technology (2014), opened July 16, 2026
- Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation — Antioxidants (Basel) (2021), opened July 16, 2026
- Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. — Clinical, Cosmetic and Investigational Dermatology (tier 3); independent academic group, 'no conflicts of interest', NCT01542138 (2013), opened October 13, 2026
- Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. — British Journal of Dermatology (tier 1); P&G co-authors; COMBINATION (niacinamide + NAG) (2010), opened October 13, 2026
- Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. — Experimental Dermatology (tier 2); P&G co-authors; receipt for the dose-response and reversibility finding (2005), opened October 13, 2026
- Synergistic effects of niacinamide and low pH on melanin synthesis, melanocyte function and hyperpigmentation: In vitro and clinical insights. — International Journal of Cosmetic Science (tier 3); P&G-authored; NOT counted (randomization not stated in abstract) (2026), opened October 13, 2026
- Topical treatment for postinflammatory hyperpigmentation: a systematic review. — Journal of Dermatological Treatment (unlisted -> tier 3); per-STUDY modified GRADE, no body-of-evidence certainty for niacinamide (2022), opened October 13, 2026
- Reduction in the appearance of facial hyperpigmentation by topical N-undecyl-10-enoyl-L-phenylalanine and its combination with niacinamide. — Journal of Cosmetic Dermatology (tier 3); P&G; NOT counted (abstract does not report niacinamide-alone vs vehicle) (2009), opened October 13, 2026
← Back to the verdict All hyperpigmentation products → Disclose a concentration or correct a fact →
for Dark Spots
Niacinamide has early or mechanistic evidence for dark spots — a reasonable bet, not a recommendation; the other actives here are not yet assessed for it.
The lead active has early or mechanistic evidence only, or is present below a working level. A reasonable bet, not a recommendation.
- Rule
- R9 → Unproven. An active with early or mechanistic evidence only; the product’s category job is not a recognised companion to the concern.
q1 = plausible · supportive = false
Why this rule exists: Plausible-tier actives alone do not earn a recommendation, and 'not for this' would overstate the case against them. 'Unproven' with the evidence dots lets the reader judge the bet (added 0.2.0 after the first shadow run put a 10% niacinamide serum at 'not for this' for hyperpigmentation). 0.5.0: the closing clause reads the other heroes — "nothing else here addresses it" only when every other active has a researched 'none' row; "not yet assessed" when that is the truth. Rows whose dots read moderate or better now reach R9p first.
Rule R9 decided 4,156 verdicts across the catalog; “Unproven” is the verdict on 4,156 of 45,446. The full register. - Carrying active
- Niacinamide
- 1 · Standing
- Plausible — trials support it
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
- 3 · Tolerability
- Gentle
- Evidence dots
- Limited evidence
- What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- October 9, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- Treatment of Solar Lentigines: A Systematic Review of Clinical Trials — Journal of Cosmetic Dermatology — searched PubMed/MEDLINE, EMBASE, Cochrane and clinicaltrials.gov to Dec 2023; 41 trials, 3,234 patients; identified ZERO niacinamide trials (2025), opened July 16, 2026
- Role of interleukin-6 and endothelin-1 receptors in enhanced melanocyte dendricity of facial spots and suppression of their ligands by niacinamide and tranexamic acid — Journal of the European Academy of Dermatology and Venereology — MECHANISM ONLY; P&G-authored; concludes effects 'warrant further human clinical validation' (2024), opened July 16, 2026
- The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer — British Journal of Dermatology — VERIFIED BUT EXCLUDED: endpoint is undifferentiated 'facial hyperpigmentation', NOT discrete lentigines (2002), opened July 16, 2026
← Back to the verdict All dark spots products → Disclose a concentration or correct a fact →
Not judged as a mask: works within its wear time, benefit outlasts the mask, comes off cleanly cannot yet be measured from the ingredient list (only intensity without injury can).
Listed for Dullness, with no verdict: the actives here have no evidence row for that concern yet. That is a gap in our table, not a mark against the product.
- Dullness: The actives here (Niacinamide, sea buckthorn extract, vitamin c derivatives, Glutathione) are in the research queue for dullness; no verdict until their rows are written.
A verdict is Dermington’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Every rule is public and the same for every product; a brand cannot buy a reading. How we decide · what has changed · disclaimer.